Loading...

Welcome to N4 Pharma

We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

Watch our video animation below to see Nuvec® in action:

Information for investors

Are you an investor? Visit the dedicated area of the website to view information on the AIM rule 26, company presentations and reports. The latest regulatory news updates are also available.

View investor information

Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!

Latest news and updates

The data – evidence based results

January 4th, 2023|

As a result of recently completed initial testing in vitro on loaded Nuvec®  with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec®  works to deliver [...]